By: Yumi Oh, Sujeong Kim, Yunjae Kim, Hyun Kim, Seungjae Shin, Soo-Jin Lee, Jiwon Kim, Sang Eun Lee, Yoojin Yang, Dohee Kim, Hae Rim Jung, Sangjin Kim, Jihui Kim,, Beomki Cho, Hansoo Park, Sung-Yup Cho
Immune checkpoint therapy (ICT) provides durable responses in select cancer patients, yet resistance remains a significant challenge, prompting the exploration of underlying molecular mechanisms. Tyrosylprotein sulfotransferase-2 (TPST2), known for its role in protein tyrosine O-sulfation, has been suggested to modulate the extracellular protein-protein interactions, but its specific role in cancer immunity remains largely unexplored.